Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Whole Exome and Transcriptome Sequencing Analysis for the Identification of Prognostic Biomarkers in Patients With Non-Small Cell Lung Cancer (NSCLC) - Hellenic Cooperative Oncology Group (HeCOG)

NCT07900581 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07900581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Whole Exome and Transcriptome Sequencing Analysis for the Identification of Prognostic Biomarkers in Patients With Non-Small Cell Lung Cancer (NSCLC) - Hellenic Cooperative Oncology Group (HeCOG)
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Observational
Overall status
Recruiting
Start date
December 11, 2021
Completion date
December 31, 2026
Enrollment
300 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)

Arms

As registered; 1 arm.

  • Patients with histologically confirmed non-small cell lung.

    Patients with histologically confirmed non-small cell lung cancer providing tumor tissue and blood samples for genomic and transcriptomic analyses, including whole-exome sequencing, RNA sequencing, and ctDNA analysis in a subset of patients.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Prevalence of genomic alterations, TMB levels, and mRNA-based immune subtypes Baseline

    Percentage of Greek NSCLC patients presenting with specific oncogenic drivers, clinically actionable mutations, germline pathogenic/likely pathogenic variants, Tumor Mutational Burden (TMB) signatures, and distinct transcriptomic mRNA-based immune subtypes.

Lead sponsor's other trials

Hellenic Cooperative Oncology Group, most recent start first.

Similar trials

Same condition (Carcinoma, Non-Small-Cell Lung) and phase, most recent start first.